“Erlotinib As Second-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors”. Journal of Analytical Oncology, vol. 4, no. 3, June 2015, pp.  94-101, https://doi.org/10.6000/1927-7229.2015.04.03.1.